Jan 25, 2026
How do romosozumab, teriparatide, and bisphosphonates compare in head‑to‑head fracture outcomes?
Romosozumab and teriparatide—both osteoanabolic agents—generally outperform oral bisphosphonates for reducing vertebral and clinical fractures in high‑risk postmenopausal populations in randomized and...